<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Paraldehyde (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Paraldehyde (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Paraldehyde (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F14280312"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiseizure Agent, Miscellaneous;</li>
<li>
                        Anxiolytics, Sedatives, and Hypnotics, Miscellaneous</li></ul></div>
<div class="block doa drugH1Div" id="F14280362"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">Canadian labeling: Second- or third-line therapy: <b>Note:</b> Do not administer &gt;5 mL per injection site.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a9679052-03a5-40df-ba72-b799a014c1cc">Alcohol withdrawal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Alcohol withdrawal:</b> IM: 5 mL every 4-6 hours for 24 hours (maximum: 30 mL on day 1), followed by every 6 hours (maximum: 20 mL/day).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c810afd-01bd-4651-a7d0-8e6e62fa9dec">Hypnotic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypnotic:</b> IM: 10 mL.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6f9ed020-ffc2-4e5d-90e9-7791e3f98146">Sedative</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sedative:</b> IM: 5 mL.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9995b785-8baa-422d-bf6f-a51de5769903">Seizure associated with status epilepticus, tetanus, or poisoning</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizure associated with status epilepticus, tetanus, or poisoning:</b> IM: 5-10 mL.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990349"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment provided in manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987721"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Mild-to-moderate impairment: No dosage adjustment provided in manufacturer's labeling; however, undergoes extensive hepatic metabolism and should be used with extreme caution. Consider dose reductions.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Severe impairment: Use contraindicated.</p></div>
<div class="block dop drugH1Div" id="F14280361"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">Canadian labeling: Second- or third-line therapy: <b>Note:</b> Do not administer &gt;5 mL per injection site.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c810afd-01bd-4651-a7d0-8e6e62fa9dec">Hypnotic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>Hypnotic:</b> IM: 0.3 mL/kg/daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6f9ed020-ffc2-4e5d-90e9-7791e3f98146">Sedative</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>Sedative:</b> IM: 0.15 mL/kg/daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="92a73c35-bcba-4685-aff2-29295b16cf07">Seizure associated with status epilepticus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>Seizure associated with status epilepticus:</b> IM: 0.1 to 0.15 mL/kg/dose every 4 to 8 hours.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51152713"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51152714"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Mild-to-moderate impairment: There are no dosage adjustments provided in the manufacturer's labeling; however, undergoes extensive hepatic metabolism and should be used with extreme caution. Consider dose reductions.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: Use contraindicated.</p></div>
<div class="block adr drugH1Div" id="F245787"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Dizziness, drowsiness, drug dependence (psychological and physical dependence with prolonged use)</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Diaphoresis, skin rash</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Metabolic acidosis</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Halitosis</p>
<p style="text-indent:-2em;margin-left:2em;">Genitourinary: Nephrosis</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic: Toxic hepatitis</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Injection site reaction (exfoliation of skin, fat necrosis, muscle irritation, nerve damage [including permanent damage], sterile abscess), pain at injection site</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Muscle cramps, tremor</p></div>
<div class="block coi drugH1Div" id="F245802"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to paraldehyde or any component of the formulation; severe hepatic insufficiency; bronchopulmonary disease; pregnancy </p></div>
<div class="block war drugH1Div" id="F245785"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Toxic hepatitis has been reported following prolonged use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Metabolic acidosis: Has been reported following prolonged use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal effects: Nephrosis has been reported following prolonged use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Avoid or use with caution in patients with cardiovascular disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with extreme caution and monitor closely for toxicity; large portions of the dose are metabolized via the liver; use is contraindicated in severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: The lungs are responsible for a significant portion of elimination of unchanged paraldehyde. Avoid or use caution in patients with respiratory disease; use is contraindicated in patients with bronchopulmonary disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sedatives: Effects with other sedative drugs or ethanol may be potentiated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: Per Canadian manufacturer's labeling, product is intended for IM administration only; avoid injecting IM near nerve trunks due to potential for severe and permanent nerve damage. IM administration is associated with severe pain and may also cause skin reactions (eg, sterile skin abscesses, skin sloughing), fat necrosis, and muscle irritation. Subcutaneous injections are <b>not</b> recommended; paraldehyde is a tissue irritant. In addition, do <b>not</b> inject intravenously due to potential for thrombophlebitis, pulmonary edema and hemorrhage, respiratory distress, cyanosis, hypotension and cardiac dilatation, and circulatory collapse.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not appropriate as a first-line agent for any indication. Limited published information exists for paraldehyde use compared to more conventional agents with more published safety and efficacy data. If used as a hypnotic/sedative agent, therapy should be limited to short-term use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Decomposition: Paraldehyde decomposes when opened; prepare using only freshly opened vials. Use of partly decomposed paraldehyde is hazardous and may result in metabolic acidosis; use of decomposed paraldehyde has resulted in death from corrosive poisoning. If solution is a brownish color or smells of acetic acid, it should <b>not</b> be used.</p>
<p style="text-indent:-2em;margin-left:4em;">• Irritant/solvent: Avoid contact with skin, eyes, and clothing. Since paraldehyde is a solvent, contact with plastic (eg, plastic syringes) or rubber should be avoided.</p>
<p style="text-indent:-2em;margin-left:4em;">• Withdrawal: Use caution when withdrawing therapy after prolonged use in physically dependent patients; decrease slowly and monitor for withdrawal symptoms.</p></div>
<div class="block prod-avail drugH1Div" id="F14280372"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the US</p></div>
<div class="block geq drugH1Div" id="F53040704"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block adm drugH1Div" id="F245799"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IM: Administer by IM injection only; avoid injecting near nerve trunks (permanent nerve damage may occur). IM injection is associated with extreme pain and serious injection site reactions.</p>
<p style="text-indent:-2em;margin-left:2em;">Do <b>not</b> administer intravenously (life-threatening effects may result) or SubQ.</p>
<p style="text-indent:-2em;margin-left:2em;">Do <b>not</b> use any use plastic syringes or rubber for administration; glass syringes are recommended for administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Do <b>not</b> use if solution is brownish or has an odor of acetic acid. Use immediately after opening vial (paraldehyde decomposes to acetic acid causing toxicity).</p></div>
<div class="block admp drugH1Div" id="F52614109"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IM:</p>
<p style="text-indent:-2em;margin-left:2em;">Administer by IM injection only; not for IV (life-threatening effects may result) or SubQ (irritating to tissues) administration. Administer undiluted by deep IM injection into the buttocks; avoid injecting near nerve trunks (permanent nerve damage may occur). Do not administer more than 5 mL per injection site. Do not use if solution is brownish or has an odor of acetic acid. Use immediately after opening vial (paraldehyde decomposes to acetic acid causing toxicity).</p>
<p style="text-indent:-2em;margin-left:2em;">Do <b>not</b> use any use plastic syringes or rubber for administration; glass syringes are recommended for administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Avoid contact with skin, eyes, and clothing.</p></div>
<div class="block hazard drugH1Div" id="F49132653"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent; use appropriate precautions for handling and disposal (EPA, U-listed).</p></div>
<div class="block use drugH1Div" id="F245798"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not approved in the United States.</p>
<p style="text-indent:-2em;margin-left:2em;">Alternative agent (only when conventional treatment is ineffective, inappropriate, or unavailable) in the treatment of convulsive seizure episodes associated with status epilepticus, tetanus, and convulsant drug toxicity. Historically, has also been used as a sedative/hypnotic, as an anxiolytic during withdrawal from opioids or barbiturates, and in the management of acute agitation or delirium due to alcohol withdrawal; however, these uses are not recommended due to the availability of safer and more efficacious agents.</p></div>
<div class="block mst drugH1Div" id="F56412980"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299823"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F245789"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the CNS depressant effect of Paraldehyde.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disulfiram: May increase the serum concentration of Paraldehyde.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53589544"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Pregnancy should be excluded prior to initiating in females of childbearing potential.</p></div>
<div class="block pri drugH1Div" id="F14280313"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Paraldehyde crosses the placenta; use in pregnancy is contraindicated. Use in obstetric anesthesia is not appropriate due to potential respiratory depression in neonates.</p></div>
<div class="block brc drugH1Div" id="F14280315"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the nursing infant, breastfeeding is not recommended.</p></div>
<div class="block pha drugH1Div" id="F245783"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Paraldehyde, a cyclic trimer of acetaldehyde, has an unknown mechanism of action; causes CNS depression, including the ascending reticular activating system to provide sedation/hypnosis and antiseizure activity (at slightly lower doses than those required to produce hypnosis). It has no analgesic properties at sub-anesthetic doses and may cause excitement or delirium in the presence of pain.</p></div>
<div class="block phk drugH1Div" id="F245801"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of sedation/hypnosis: IM: 5-15 minutes</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: 8 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: IM: Rapid</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Tissue distribution not extensively studied; diffuses into CSF with concentrations in CSF ~25% to 30% lower than that of serum concentrations</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: ~80% to 90% of the dose metabolized in the liver to acetaldehyde, then oxidized via aldehyde dehydrogenase to acetic acid, and further metabolized to carbon dioxide and water</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Adults: ~3.5-9.5 hours (mean: 7.5 hours [in patients with normal hepatic function])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: IM: Serum: 20-60 minutes; CSF: 30-60 minutes</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Significant portion excreted as unchanged drug in expired air via the lungs; trace amounts excreted in urine unchanged </p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-16698412">
<a name="16698412"></a>Ahmad S, Ellis JC, Kamwendo H, et al, “Efficacy and Safety of Intranasal Lorazepam Versus Intramuscular Paraldehyde for Protracted Convulsions in Children: An Open Randomised Trial,” <i>Lancet</i>, 2006, 367(9522):1591-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paraldehyde-united-states-not-available-drug-information/abstract-text/16698412/pubmed" id="16698412" target="_blank">16698412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2666958">
<a name="2666958"></a>Guthrie SK, “The Treatment of Alcohol Withdrawal,” <i> Pharmacotherapy</i>, 1989, 9(3):131-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paraldehyde-united-states-not-available-drug-information/abstract-text/2666958/pubmed" id="2666958" target="_blank">2666958</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Healthcare Environmental Resource Center (HERC). Pharmaceuticals—Hazardous Waste. http://www.hercenter.org/hazmat/pharma.cfm#listed. Published 2015. Accessed October 23, 2016.</div>
</li>
<li>
<div class="reference">
                  National Institute for Health and Clinical Excellence (NICE), “The Epilepsies: The Diagnosis and Management of the Epilepsies in Adults and Children in Primary and Secondary Care,” 2012. Available at  http://guidance.nice.org.uk/CG137/Guidance/pdf/English
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19941525">
<a name="19941525"></a>Rossetti AO, “Novel Anesthetics and Other Treatment Strategies for Refractory Status Epilepticus,” <i>Epilepsia</i>, 2009, 50(Suppl 12):51-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paraldehyde-united-states-not-available-drug-information/abstract-text/19941525/pubmed" id="19941525" target="_blank">19941525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19357123">
<a name="19357123"></a>Rowland AG, Gill AM, Stewart AB, et al, “Review of the Efficacy of Rectal Paraldehyde in the Management of Acute and Prolonged Tonic-Clonic Convulsions,” <i>Arch Dis Child</i>, 2009, 94(9):720-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paraldehyde-united-states-not-available-drug-information/abstract-text/19357123/pubmed" id="19357123" target="_blank">19357123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19158332">
<a name="19158332"></a>Yoong M, Chin RF, and Scott RC, “Management of Convulsive Status Epilepticus in Children,” <i>Arch Dis Child Educ Pract Ed</i>, 2009, 94(1):1-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paraldehyde-united-states-not-available-drug-information/abstract-text/19158332/pubmed" id="19158332" target="_blank">19158332</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 83875 Version 131.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
